BRAF inhibitors are now the first-line treatment for patients with unresectable or metastatic melanoma which test is positive for BRAFV600, in accordance with the recommendations of the health authorities such as the National Comprehensive Cancer Network and European guidelines [11, 12]. This evidence concerns the gene BRAF and metastatic melanoma.